Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Seeking Alpha / 1 Views

Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib
Mr. Northcott brings over 20 years of biopharmaceutical experience building commercial organizations and successfully commercializing novel products, including BTK inhibitor ibrutinib

Comments